At the time of writing, Immunome Inc [IMNM] stock is trading at $27.34, up 3.80%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IMNM shares have gain 12.98% over the last week, with a monthly amount glided 18.30%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 7, March 2024, Immunome to Participate in the Leerink Partners Global Biopharma Conference. In a post published today on Yahoo Finance, Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, Ph.D., President and CEO of Immunome, will present at the Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12, 2024 at 4:20 p.m. ET.
From an analyst’s perspective:
Immunome Inc [NASDAQ: IMNM] stock has seen the most recent analyst activity on January 29, 2024, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $30. Previously, Wedbush started tracking the stock with Outperform rating on December 19, 2023, and set its price target to $12. On October 29, 2021, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $35 on the stock.
For the past year, the stock price of Immunome Inc fluctuated between $4.18 and $27.82. Immunome Inc [NASDAQ: IMNM] shares were valued at $27.34 at the most recent close of the market.
Analyzing the IMNM fundamentals
Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -2.22%, Pretax Profit Margin comes in at -2.15%, and Net Profit Margin reading is -2.2%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -1.95 and Total Capital is -0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.78 points at the first support level, and at 24.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.93, and for the 2nd resistance point, it is at 32.52.
Immunome Inc [IMNM] reported earnings per share of -$0.46 for its fiscal quarter that ended on 6/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.16/share, meaning a difference of -$0.3 and a surprise factor of -187.50%. By comparison, the stated earnings for the previous quarter ended on 3/30/2023 were -$0.35 per share as compared to estimates of $0.58 per share, a difference of -$0.93 representing a surprise of -160.30%.
Ratios To Look Out For
It is important to note that Immunome Inc [NASDAQ:IMNM] has a current ratio of 3.96. Also, the Quick Ratio is 3.96, while the Cash Ratio stands at 3.92. Considering the valuation of this stock, the price to sales ratio is 149.36, the price to book ratio is 54.91.
Transactions by insiders
Recent insider trading involved SIEGALL CLAY B, President and CEO, that happened on Oct 02 ’23 when 0.17 million shares were purchased. Chief Strategy Officer, Turner Bruce completed a deal on Oct 02 ’23 to buy 42300.0 shares.
